[1] X. Wang et al., “Spatiotemporal epidemiology of, and factors associated with, the tuberculosis prevalence in northern China, 2010-2014,” BMC Infect. Dis., vol. 19, p. 365, 2019.
[2] A. Alelign, A. Zewude, T. Mohammed, S. Tolosa, G. Ameni, and B. Petros, “Molecular detection of Mycobacterium tuberculosis sensitivity to rifampicin and isoniazid in South Gondar Zone, northwest Ethiopia,” BMC Infect. Dis., vol. 19, p. 343, 2019.
[3] J. Shi et al., “GeneXpert MTB/RIF Outperforms Mycobacterial Culture in Detecting Mycobacterium tuberculosis from Salivary Sputum,” Biomed Res. Int., vol. 2018, 2018.
[4] L. Jordao and O. V Vieira, “Tuberculosis: New Aspects of an Old Disease,” Int. J. Cell Biol., vol. 2011, 2011.
[5] C. B. Duru, K. A. Uwakwe, K. C. Diwe, C. C. Nnebue, H. N. Chineke, and C. A. Emerole, “Prevalence of Active Pulmonary Tuberculosis among HIV Positive Patients Attending Adult HIV Clinic in a Teaching Hospital in Imo State, South East, Nigeria: A 6 Year Review (2006-2012),” Indian J. Med. Res. Pharm. Sci., vol. 1, no. 6, 2014.
[6] T. Ahmad, M. A. Jadon, M. Nasir, and M. N. K. Khattak, “Prevalence of sputum smear positive pulmonary tuberculosis at Dargai, District Malakand, Pakistan: A four year retrospective study,” Egypt. J. Chest Dis. Tuberc., vol. 65, no. 2, pp. 461–464, 2016.
[7] N. S. Hochberg et al., “The complexity of diagnosing latent tuberculosis infection in older adults in long-term care facilities,” Int. J. Infect. Dis., vol. 44, pp. 37–43, 2016.
[8] H. Kipruto et al., “The epidemiology of tuberculosis in Kenya, a high TB/HIV burden country (2000-2013),” Int. J. Public Heal. Epidemiol. Res., vol. 1, no. 1, pp. 002–013, 2015.
[9] D. Bikila et al., “Seasonality and Trend Analysis of Pulmonary Tuberculosis at St. Paul Hospital Millennium Medical,” Austin J. Pulm. Respir. Med., vol. 4, no. 2, p. 1054, 2017.
[10] E. Ejeta, M. Legesse, and G. Ameni, “Preliminary Study on the Epidemiology of Tuberculosis in Nekemte and Its Surroundings -Western Ethiopia,” Sci. Technol. Arts Res., vol. 1, no. 1, pp. 18–25, 2012.
[11] G. Aryee et al., “Estimating the incidence of tuberculosis cases reported at a tertiary hospital in Ghana: a time series model approach,” BMC Public Health, vol. 18, p. 1292, 2018.
[12] M. P. Kwabla, D. K. Ameme, and P. Nortey, “Pulmonary Tuberculosis and Its Risk Factors among Inmates of a Ghanaian Prison,” Int. J. Trop. Dis. Heal., vol. 9, no. 3, pp. 1–10, 2015.
[13] A. N. Eteudo et al., “A Correlation between Tuberculosis Infection and Coagulation Parameters (In Mile Four Hospital, Abakaliki),” Ann. Adv. Med. Sci., vol. 1, no. 1, 2017.
[14] S. Janssen et al., “Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis : A Prospective Cohort Study,” J. Infect. Dis., vol. 215, pp. 247–258, 2017.
[15] L. M. Kager et al., “Pulmonary tuberculosis induces a systemic hypercoagulable state,” J. Infect., vol. 70, pp. 324–334, 2015.
[16] A. Gupta and R. Dixit, “Pulmonary Tuberculosis: A Neglected Risk Factor for Deep Venous Thrombosis,” Int. J. Mycobacteriology, vol. 6, no. 2, pp. 184–6, 2017.
[17] A. Gupta, P. Mrigpuri, A. Faye, D. Bandyopadhyay, and R. Singla, “Pulmonary tuberculosis ‑ An emerging risk factor for venous thromboembolism: A case series and review of literature,” Lung India, vol. 34, no. 1, pp. 65–9, 2017.
[18] H. Kwas, S. Habibech, I. Zendah, and I. Elmjendel, “Pulmonary embolism and tuberculosis,” Asian Cardiovasc. Thorac. Ann., vol. 22, no. 4, pp. 487–490, 2014.
[19] A. S. Kutiyal, N. Gupta, S. Garg, and H. S. Hira, “A Study of Haematological and Haemostasis Parameters and Hypercoagulable State in Tuberculosis Patients in Northern India and the Outcome with Anti-Tubercular Therapy,” J. Clin. Diagnostic Res., vol. 11, no. 2, pp. OC09-OC13, 2017.
[20] E. Kassa, B. Enawgaw, A. Gelaw, and B. Gelaw, “Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia,” BMC Hematol., 2016.
[21] D. Kahase, A. Solomon, and M. Alemayehu, “Evaluation of Peripheral Blood Parameters of Pulmonary Tuberculosis Patients at St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia: Comparative Study,” J. Blood Med., vol. 11, pp. 115–121, 2020.
[22] K. W. M. P. P. Kumarihamy, D. M. P. U. K. Ralapanawa, and W. A. T. A. Jayalath, “A rare complication of pulmonary tuberculosis: a case report,” BMC Res. Notes, vol. 8, p. 39, 2015.
[23] K. Wangdi and M. R. Gurung, “The epidemiology of tuberculosis in Phuentsholing General Hospital: a six-year retrospective study,” BMC Res. Notes, vol. 5, no. 1, p. 311, 2012.
[24] S.-H. Wang, B. Carruthers, and J. Turner, “The Influence of Increasing Age on Susceptibility of the Elderly to Tuberculosis,” Open Longev. Sci., vol. 6, pp. 73–82, 2012.
[25] R. Byng-Maddick and M. Noursadeghi, “Does tuberculosis threaten our ageing populations?,” BMC Infect. Dis., vol. 16, p. 119, 2016.
[26] A. Mukherjee, I. Saha, A. Sarkar, and R. Chowdhury, “Gender differences in notification rates, clinical forms and treatment outcome of tuberculosis patients under the RNTCP,” Lung India, vol. 29, no. 2, pp. 120–122, 2012.
[27] P. Chinnakali, K. Selvaraj, P. Thekkur, G. Ramasamy, M. Thulasingam, and K. Vasudevan, “Age and Sex Differences in Sputum Smear Microscopy Results for Acid Fast Bacilli in a Tertiary Care Centre, South India,” J. Respir. Med., vol. 2014, 2014.
[28] J. Feng et al., “Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study,” Clin. Microbiol. Infect., vol. 18, no. 9, pp. E331–E337, 2012.
[29] O. Turken et al., “Hemostatic changes in active pulmonary tuberculosis,” Int. J. Tuberc. Lung Dis., vol. 6, no. 10, pp. 927–932, 2002.
[30] R. A. Marlar and J. N. Gausman, “Laboratory testing issues for protein C, protein S, and antithrombin,” Int. J. Lab. Hematol., vol. 36, pp. 289–295, 2014.
[31] C. Teresa, K. A. Mathews, A. C. G. Abrams-Ogg, and D. Wood, “The Link Between Inflammation and Coagulation: Influence on the Interpretation of Diagnostic Laboratory Tests,” Compend. Contin. Educ. Vet., pp. E1–E12, 2011.
[32] K. Koyama, S. Katayama, K. Tonai, J. Shima, T. Koinuma, and S. Nunomiya, “Biomarker profiles of coagulopathy and alveolar epithelial injury in acute respiratory distress syndrome with idiopathic/immune-related disease or common direct risk factors,” Crit. Care, vol. 23, p. 283, 2019.
[33] B. Koscielniak, E. Wypasek, and A. Undas, “Determinants of Elevated Levels of Natural Anticoagulants in Healthy Subjects,” Adv. Clin. Exp. Med., vol. 24, no. 5, pp. 791–800, 2015.
[34] M. C. Pintao et al., “Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study,” Blood, vol. 122, no. 18, pp. 3210–3219, 2019.
[35] E. I. Obeagu, I. L. Okoroiwu, H. U. Nwanjo, and D. C. Nwosu, “Evaluation of haematological parameters of tuberculosis patients in Umuahia,” Eur. J. Pharm. Med. Res., vol. 6, no. 7, pp. 693–699, 2019.
[36] K. Rohini, M. S. Bhat, P. S. Srikumar, and A. M. Kumar, “Assessment of Hematological Parameters in Pulmonary Tuberculosis Patients,” Indian J. Clin. Biochem., vol. 31, no. 3, pp. 332–335, 2016.
[37] J. A. Olaniyi, O. M. Ige, S. K. Rahamon, and O. G. Arinola, “Haematological Abnormalities in Treatment Naive Multidrug- Resistant Tuberculosis Patients with or Without Human Immunodeficiency Virus (HIV) Infection,” Arch. Basic Appl. Med., vol. 4, pp. 57–62, 2016.
[38] J. D. Padhariya and S. N. Shah, “Haematological Profile of Patients of Pulmonary Tuberculosis,” Ann. Pathol. Lab. Med., vol. 6, no. 10, 2019.
[39] E. Tozkoparan, O. Deniz, E. Ucar, H. Bilgic, and K. Ekiz, “Changes in platelet count and indices in pulmonary tuberculosis,” Clin. Chem. Lab. Med., vol. 45, no. 8, pp. 1009–1013, 2007.
[40] Ş. Füsun, E. Yazar, and P. Yıldız, “Prominent features of platelet count, plateletcrit, mean platelet volume and platelet distribution width in pulmonary tuberculosis,” Multidiscip. Respir. Med., vol. 7, p. 38, 2012.
[41] M. F. Yacoub, H. F. Ferwiz, and F. Said, “Effect of Interleukin and Hepcidin in Anemia of Chronic Diseases,” Anemia, vol. 2020, 2020.
[42] G. Weiss and L. T. Goodnough, “Anemia of Chronic Disease,” N. Engl. J. Med., vol. 352, pp. 1011–1023, 2005.
[43] E. Poggiali, M. M. De Amicis, and I. Motta, “Anemia of chronic disease: A unique defect of iron recycling for many different chronic diseases,” Eur. J. Intern. Med., vol. 25, no. 1, pp. 12–17, 2014.
[44] P. A. Akpan, J. O. Akpotuzor, and E. C. Akwiwu, “Some Haematological Parameters of Tuberculosis (TB) Infected Africans: The Nigerian Perspective,” J. Nat. Sci. Res., vol. 2, no. 1, 2012.
[45] I. M. Okafor, A.-A. O. Eyo, E. A. Okon, and P. A. Akpan, “Some Haematological Parameters of Tuberculosis Infected Nigerians: A Study in Calabar - Nigeria,” Glob. J. Pure Appl. Sci., vol. 19, pp. 95–100, 2013.
[46] S. Iqbal, U. Ahmed, and M. A. Khan, “Haematological parameters altered in tuberculosis,” Pak J Physiol, vol. 11, no. 1, pp. 13–16, 2015.
[47] Q. Chai, Y. Zhang, and C. H. Liu, “Mycobacterium tuberculosis: An Adaptable Pathogen Associated With Multiple Human Diseases,” Front. Cell. Infect. Microbiol., vol. 8, pp. 1–15, 2018.
[48] S. Rathod, D. R. Samel, P. Kshirsagar, and M. Pokar, “Thrombocytosis: can it be used as a marker for tuberculosis?,” Int. J. Res. Med. Sci., vol. 5, no. 7, pp. 3082–3086, 2017.
[49] R. Kurup, K. Flemming, S. Daniram, S. Marks-James, and R. R. Martin, “Hematological and Biochemistry Profile and Risk Factors Associated with Pulmonary Tuberculosis Patients in Guyana,” Tuberc. Res. Treat., vol. 2016, 2016.
[50] G. Gunluoglu, E. E. Yazar, N. S. Veske, E. C. Seyhan, and S. Altin, “Mean platelet volume as an inflammation marker in active pulmonary tuberculosis,” Multidiscip. Respir. Med., vol. 9, p. 11, 2014.
[51] A. A. Renshaw and E. W. Gould, “Thrombocytosis Is Associated With Mycobacterium tuberculosis Infection and Positive Acid-Fast Stains in Granulomas,” Am J Clin Pathol, vol. 139, pp. 584–586, 2013.
[52] S. H. Sadek, S. Farghaly, M. A. A. Abdou, and M. H. M. Abdel-Rahim, “Bedside inflammatory mediators in pulmonary tuberculosis,” Egypt. J. Bronchol., vol. 11, pp. 260–267, 2017.